Ageing and inflammation strongly drive the risk of cardiovascular disease. Work over the
past decade has uncovered a common condition characterized by the positive selection of …

Polycythemia vera (PV) is a relatively indolent myeloid neoplasm with median survival that
exceeds 35 years in young patients, but its natural history might be interrupted by …

Abstract Disease Overview Polycythemia vera (PV) is a JAK2‐mutated myeloproliferative
neoplasm characterized by clonal erythrocytosis; other features include leukocytosis …

The goal of therapy for patients with essential thrombocythemia (ET) and polycythemia vera
(PV) is to reduce thrombotic events by normalizing blood counts. Hydroxyurea (HU) and …

Background Current treatment recommendations for patients with polycythemia vera call for
maintaining a hematocrit of less than 45%, but this therapeutic strategy has not been tested …

Background: Patients with myeloproliferative neoplasms (MPNs) are reported to be at
increased risk for thrombotic events. However, no population-based study has estimated this …

Inflammation contributes centrally to cardiovascular diseases, and anti-inflammatory
treatments can reduce cardiovascular events. The JAK–STAT pathway is an emerging target …

Prior studies have reported high response rates with recombinant interferon-α (rIFN-α)
therapy in patients with essential thrombocythemia (ET) and polycythemia vera (PV). To …

Background In the pivotal RESPONSE study, ruxolitinib, a Janus kinase (JAK) 1 and JAK2
inhibitor, was superior to best available therapy at controlling haematocrit and improving …

We present a review of critical concepts and produce recommendations on the management
of Philadelphia-negative classical myeloproliferative neoplasms, including monitoring …